Cover Image
市場調查報告書

PharmaPoint:精神分裂症 - 日本的醫藥品的預測與市場分析

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 299164
出版日期 內容資訊 英文 133 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:精神分裂症 - 日本的醫藥品的預測與市場分析 PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 133 Pages
簡介

精神分裂症是持續性的長期性腦功能障礙,造成嚴重的神經衰弱發作。其核心症狀為聽覺或視覺性幻覺(幻聽或幻視),許多時候還會伴隨妄想。也常發生學習障礙或認知障礙。根WHO專家推測全球約2,400萬人患有精神分裂症。

本報告提供日本精神分裂症的治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),以及SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 症狀

第4章 疾病的管理

  • 診斷
  • 治療概要
  • 日本
    • 診斷
    • 臨床診療

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 按產品簡介:世代

第6章 機會及未滿足需求

  • 未滿足需求概要
  • 差距分析

第7章 開發平台評估

  • 概要
  • 初期階段開發平台的評估
  • 新的治療方法
  • 長效型藥物遞輸
  • 技術趨勢分析
  • 臨床開發中的潛力藥物
    • Aripiprazole Lauroxil
    • Cariprazine
    • Brexpiprazole
    • Zicronapine
    • Bitopertin
    • EVP-6124

第8章 市場預測

  • 日本
    • 預測
    • 主要的活動
    • 推動因素與阻礙

第9章 附錄

圖表

目錄
Product Code: GDHC226CFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

The youth of Japan's schizophrenia drug market will drive a significant period of growth over the forecast period. Disease management in Japan uses LAIs less often than the countries in the EU, and the US as well. However, their growing role in schizophrenia treatment is driving a growing popularity in Japan, and the uptake of new LAI therapies should be rapid.

Scope

  • Overview of Schizophrenia including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Schizophrenia market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia
  • 4.3. Japan
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles by Generation
    • 5.3.1. Conventional Antipsychotics
    • 5.3.2. Atypical Antipsychotics

6. Opportunity and Unmet Need

  • 6.1. Unmet Needs Overview
    • 6.1.1. Public Awareness
    • 6.1.2. Early Diagnosis and Treatment
    • 6.1.3. Long-Acting and Advanced Drug Delivery Systems
    • 6.1.4. Effective Management of Negative and Cognitive Symptom Domains
  • 6.2. Gap Analysis
    • 6.2.1. Long-Acting Drug Delivery
    • 6.2.2. Treatment of Negative and Cognitive Symptoms

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Early-Stage Pipeline Assessment
  • 7.3. Novel Therapeutic Approaches
    • 7.3.1. Negative Symptoms
    • 7.3.2. Cognitive Symptoms
  • 7.4. Long-Acting Drug Delivery
  • 7.5. Technology Trends Analysis
  • 7.6. Key Drugs in Clinical Development
    • 7.6.1. Aripiprazole Lauroxil
    • 7.6.2. Cariprazine
    • 7.6.3. Brexpiprazole
    • 7.6.4. Zicronapine
    • 7.6.5. Bitopertin
    • 7.6.6. EVP-6124

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosis and Treatment Rates
    • 9.4.2. Adherence Rates
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Key Opinion Leaders
  • 9.6. About the Authors
    • 9.6.1. Author
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Chemical Classifications of FGAs
  • Table 9: Receptor Affinity Profiles for FGAs
  • Table 10: First-Generation Antipsychotics SWOT Analysis, 2013
  • Table 11: Product Profile - Abilify
  • Table 12: Abilify SWOT Analysis, 2014
  • Table 13: Product Profile - Saphris
  • Table 14: Saphris SWOT Analysis, 2013
  • Table 15: Product Profile - Clozaril
  • Table 16: Clozaril SWOT Analysis, 2014
  • Table 17: Product Profile - Fanapt
  • Table 18: Fanapt SWOT Analysis, 2014
  • Table 19: Product Profile - Latuda
  • Table 20: Latuda SWOT Analysis, 2014
  • Table 21: Product Profile - Zyprexa
  • Table 22: Zyprexa SWOT Analysis, 2014
  • Table 23: Product Profile - Invega
  • Table 24: Invega SWOT Analysis, 2013
  • Table 25: Product Profile - Seroquel
  • Table 26: Seroquel SWOT Analysis, 2013
  • Table 27: Product Profile - Risperdal
  • Table 28: Risperdal SWOT Analysis, 2013
  • Table 29: Product Profile - Geodon
  • Table 30: Geodon SWOT Analysis, 2013
  • Table 31: Unmet Needs - Current Level of Attainment
  • Table 32: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 33: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014
  • Table 34: Pipeline Candidates in Development for Schizophrenia, 2014
  • Table 35: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013
  • Table 36: Product Profile - Aripiprazole Lauroxil
  • Table 37: Aripiprazole Lauroxil SWOT Analysis, 2014
  • Table 38: Product Profile - Cariprazine
  • Table 39: Cariprazine SWOT Analysis, 2014
  • Table 40: Product Profile - Brexpiprazole
  • Table 41: Brexpiprazole SWOT Analysis, 2014
  • Table 42: Product Profile - Zicronapine
  • Table 43: Zicronapine SWOT Analysis, 2014
  • Table 44: Product Profile - Bitopertin
  • Table 45: Bitopertin SWOT Analysis, 2014
  • Table 46: Product Profile - EVP-6124
  • Table 47: EVP-6124 SWOT Analysis, 2014
  • Table 48: Sales Forecast ($m) for Schizophrenia in Japan, 2012-2022
  • Table 49: Key Events Impacting Sales for Schizophrenia in Japan, 2012-2022
  • Table 50: Schizophrenia Market in Japan - Drivers and Barriers, 2012-2022
  • Table 51: Key Launch Dates
  • Table 52: Key Patent Expirations

List of Figures

  • Figure 1: Schizophrenia - Pipeline Drugs by Target, 2014
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022
  • Figure 3: Sales for Schizophrenia in Japan by Drug Class, 2012-2022
Back to Top